Metabolic & Cardiometabolic
PCSK9 inhibitors decreases lipoprotein(a) (~20-30%)
In plain terms: Do PCSK9 inhibitors lower lipoprotein(a), the genetically-driven risk lipid?
Part of: 💊 PCSK9 inhibitors
Yes — evolocumab and alirocumab reduce Lp(a) by roughly 20-30%, a modest but real effect (smaller than for LDL and not enough to fully normalize high Lp(a)).
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
The evidence (12)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Sabatine 2015 (OSLER) venue: N Engl J Med · N Engl J Med | RCT | supports | moderate | OSLER program reported evolocumab reduced Lp(a) ~25% alongside LDL lowering, consistent with the pooled phase 2/3 magnitude. |
| Raal 2015 (RUTHERFORD-2) venue: Lancet · Lancet | RCT | supports | moderate | RUTHERFORD-2 in heterozygous FH: evolocumab lowered Lp(a) ~22-32% in addition to large LDL reductions, showing the effect holds in genetic hypercholesterolemia. |
| Dai 2023 · Endokrynol Pol | meta-analysis | supports | moderate | In familial hypercholesterolaemia, alirocumab/evolocumab significantly lowered Lp(a) versus placebo, extending the effect to a genetically high-Lp(a) population. |
| Cao 2019 · Am J Cardiovasc Drugs | meta-analysis | supports | high | Dedicated meta-analysis of 27 RCTs: PCSK9 monoclonal antibodies reduced Lp(a) by a weighted mean of ~21-27% versus placebo, robust across agents and doses. |
| Mulligan 2026 · J Clin Lipidol | meta-analysis | supports | moderate | Head-to-head meta-analysis found evolocumab, alirocumab, inclisiran and newer agents all reduce Lp(a) with no major between-agent differences. |
| Bittner 2020 (ODYSSEY OUTCOMES) venue: J Am Coll Cardiol · J Am Coll Cardiol | RCT | supports | high | ODYSSEY OUTCOMES: alirocumab lowered Lp(a) by median 5.0 mg/dL (~23%); Lp(a) reduction independently predicted fewer major CV events beyond LDL lowering. |
| Gaudet 2017 · Am J Cardiol | RCT | supports | high | Pooled ODYSSEY phase 3 (>4,900 patients): alirocumab lowered Lp(a) ~23-29% sustained over ≥1.5 years, independent of baseline Lp(a) and LDL response. |
| Farmakis 2021 · Am J Cardiovasc Drugs | meta-analysis | supports | high | Pooled 41 RCTs (64,107 patients): PCSK9 inhibitors reduced Lp(a) by 26.7% versus comparators, a robust and consistent effect. |
| Qiao 2026 · Drugs | meta-analysis | supports | high | Umbrella review of meta-analyses confirms PCSK9 inhibitors consistently lower Lp(a) by roughly 20-30% across pooled RCT evidence. |
| O'Donoghue 2019 (FOURIER) venue: Circulation · Circulation | RCT | supports | high | FOURIER: evolocumab cut Lp(a) by median 27%; higher baseline Lp(a) predicted greater CV event reduction, supporting an independent contribution. |
| Zayed 2026 · Diabetes Obes Metab | meta-analysis | mixed | moderate | Network meta-analysis shows PCSK9-directed therapy lowers Lp(a) modestly but far less than dedicated siRNA/ASO agents, so the reduction is real yet comparatively limited. |
| Raal 2014 · J Am Coll Cardiol | RCT | supports | high | Pooled analysis of 4 phase 2 evolocumab trials (1,359 patients): Lp(a) reduced 25-32% dose-dependently — the first systematic demonstration of the effect. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.